|
|
Volumn 39, Issue 3, 2000, Pages 215-231
|
|
Effects of obesity on pharmacokinetics: Implications for drug therapy
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANALGESIC AGENT;
ANESTHETIC AGENT;
ANTICONVULSIVE AGENT;
ANTIINFECTIVE AGENT;
ANTINEOPLASTIC AGENT;
ANTIOBESITY AGENT;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
BUSULFAN;
CAFFEINE;
CARBAMAZEPINE;
CARBOPLATIN;
CIPROFLOXACIN;
CYCLOPHOSPHAMIDE;
CYTOCHROME P450 ISOENZYME;
DEXFENFLURAMINE;
DOXORUBICIN;
GENTAMICIN;
GLIBENCLAMIDE;
GLIPIZIDE;
IFOSFAMIDE;
LITHIUM;
NEUROMUSCULAR BLOCKING AGENT;
PHENYTOIN;
PROPOFOL;
PSYCHOTROPIC AGENT;
REMIFENTANIL;
SUFENTANIL;
THEOPHYLLINE;
UNINDEXED DRUG;
VANCOMYCIN;
ADIPOSE TISSUE BLOOD FLOW;
ARTICLE;
BODY FAT;
BODY WEIGHT;
DOSE CALCULATION;
DRUG DISTRIBUTION;
DRUG METABOLISM;
DRUG PROTEIN BINDING;
DRUG SAFETY;
HEART PERFORMANCE;
HUMAN;
KIDNEY FUNCTION;
LIPOPHILICITY;
OBESITY;
PRIORITY JOURNAL;
|
|
EID: 0033800745
PISSN: 03125963
EISSN: None
Source Type: Journal
DOI: 10.2165/00003088-200039030-00004 Document Type: Article |
|
Times cited : (537)
|
|
References (3)
|
